近日，中国生物制药（1177.HK）1类新药安罗替尼联合派安普利单抗联合化疗用于IIB-IIIB期非小细胞肺癌（NSCLC）患者围术期治疗的三臂前瞻性临床试验研究，在线发表于《Nature》子刊《Signal Transduction and Targeted Therapy》（信号转导与靶向治疗，IF：52.7）。结果[1]显示，安罗替尼及派安普利单抗的加入能够提高患者的主要病理缓解（MPR）率...
Source Link近日，中国生物制药（1177.HK）1类新药安罗替尼联合派安普利单抗联合化疗用于IIB-IIIB期非小细胞肺癌（NSCLC）患者围术期治疗的三臂前瞻性临床试验研究，在线发表于《Nature》子刊《Signal Transduction and Targeted Therapy》（信号转导与靶向治疗，IF：52.7）。结果[1]显示，安罗替尼及派安普利单抗的加入能够提高患者的主要病理缓解（MPR）率...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.